ArticleJournal of pharmacology & pharmacotherapeutics2013
Anti-inflammatoryactivity of calciumchannel blocker lercanidipine hydrochloride.
Article in Journal of pharmacology & pharmacotherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 19 citations in OpenAlex.
- Real-World Adherence to Dihydropyridine Calcium-Channel Blockers: A Pharmacoepidemiologic Study.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026Article
- Thiazole-Substituted Benzoylpiperazines with Anti-Cancer and Anti-Inflammatory Activities: Comparative Evaluation with Lercanidipine.International journal of molecular sciences · 2026Article
- Lercanidipine Enhances Cisplatin Activity: Dual Anticancer and Anti-Inflammatory Effects via Caspase Activation and MAPK Inhibition.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Genetic evidence for amlodipine's protective role in gastroesophageal reflux disease: A focus on CACNB2.PloS one · 2025Article
- Lercanidipine ameliorated doxorubicin-induced neuroinflammation and maintained the expressions of choline acetyltransferase via enhancing the levels of PI3K/AKT/HIF1-α expressions.Molecular biology reports · 2024Article
- Effects of lercanidipine on traumatic spinal cord injury: an experimental study.Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES · 2024Article
- Elevated Serum Purine Levels in Schizophrenia: A Reverse Translational Study to Identify Novel Inflammatory Biomarkers.The international journal of neuropsychopharmacology · 2022Article
- Bromamine T, a stable active bromine compound, prevents the LPS‑induced inflammatory response.International journal of molecular medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the anti-inflammatory effect of the third-generation CCB, lercanidipine. MATERIALS AND
methodsThe ability of lercanidipine to reduce inflammation in carrageenan-induced paw edema in rats was evaluated, using different doses and its anti-inflammatory effect was compared with that of diclofenac sodium. Mast cell degranulation effect of lercanidipine was also carried out.
resultsLercanidipine produced a significant reduction in the inflammatory paw edema at all doses and at all intervals (P < 0.001). The percentage of reduction in edema was found to be proportionate to the doses of lercanidipine. Lercanidipine also significantly reduced the percentage of propranolol-induced mast cell degranulation.
conclusionsIt was found that lercanidipine exerts a positive anti-inflammatory effect in a dose-dependent manner and was superior to diclofenac sodium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.